Provisional Title: Safety Analysis of Brentuximab Vedotin From the Phase 3 AETHERA Trial in Hodgkin Lymphoma in the Posttransplant Consolidation Setting

• Brentuximab vedotin (BV) is approved for the treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression post-auto-HSCT.• BV-associated peripheral neuropathy is manageable via dose modification and is largely reversible upon treatment cessation.• Understandin g the frequency, severity, and management of BV-associated AEs can help optimize outcomes in patients with HL.

Source: Biology of Blood and Marrow Transplantation - May 30, 2018 Category: Hematology Authors: A. Nademanee, A. Sureda, P. Stiff, J. Holowiecki, M. Abidi, N.N. Hunder, M. Pecsok, M. Uttarwar, I. Purevjal, J. Sweetenham Source Type: research